The brands that win this market won't be the ones with the best peptide lineup. They'll be the ones whose prescribing, pharmacy routing, and billing don't break the next time the FDA moves a molecule between categories. We build that foundation. You're live in 8 to 10 weeks.
Peptides are short chains of amino acids, 40 or fewer, that the FDA regulates as drugs. That single distinction decides your entire regulatory pathway. Insulin, GLP-1, and oxytocin are all peptides: signals the body already knows how to read.
GLP-1s taught millions of patients to buy healthcare directly, online, on subscription. Peptides extend that behavior into recovery, cognition, and sleep. The patient acquisition playbook is proven. The compliant infrastructure is what's scarce.
The future of peptides won't be defined by the molecules themselves, but by the infrastructure built around them. Regulation is evolving, and the companies preparing today will be the ones ready to lead tomorrow.
No six-week discovery phase that produces a slide deck. We scope hard up front, then ship in weekly increments you can click through.
Your model, your states, and your partners mapped against the current regulatory picture. We fix the scope and the price before anyone writes code.
A fixed scope, a fixed price, and an architecture your counsel can review.
Auth, HIPAA infrastructure, Rx gating, and the provider and patient portals, stood up from components that already work.
A clickable portal on your own domain.
E-prescribing, provider review, and pharmacy routing wired together, then tested against real cases instead of happy paths.
A prescription that travels from intake to a pharmacy.
Intake logic, risk model, subscriptions, retention flows, and your brand. The part nobody else can copy off you.
The product that makes you different from the other forty portals.
Compliance review, BAAs in place across every data handler, failure testing, then go live and keep shipping.
A live platform, and the keys to it.
The people who scope it build it. No transition from a sales team to a delivery team you've never met.
You know the number before we start. Scope changes are a conversation, not a surprise invoice.
Rx gating and audit trails land with the first commit. Retrofitting them costs more than building them.
We build to the regulatory model your counsel signs off on, and flag when an architecture choice creates exposure.
| Comparison | Full custom | Build with us | White-label |
|---|---|---|---|
| Time to launch | 8 months | 8 to 10 weeks | 4 to 6 weeks |
| Who owns the code | You | You | The vendor |
| Differentiation | Total | Total | You look like everyone else |
| Swap a pharmacy or EHR | Possible, expensive | Built for it | Whatever they support |
| Cost shape | $500K+ and rising | Fixed build, then it's yours | Monthly, forever, per seat |
| Regulatory change hits | You rebuild | Config, not rewrite | You wait for their roadmap |
Pick the capabilities you need. You get an indicative range, a timeline, and a live view of your platform as a connected chain.
Indicative ranges to scope the conversation, not a quote.
A peptide clinic is only as strong as the systems behind it. We connect the tools you already trust and enforce compliance where it counts, so a patient can only ever pay for what a licensed provider prescribed.
Bring your own licensed clinicians and we build the queue, credentialing records and state licensing rules around them. Don't have a panel yet, or need coverage in a state you're not licensed in? We plug into a provider network like Openloop instead — same platform, same compliance layer, providers sourced on demand. Start on a network to launch, move to your own panel as you grow, or run both side by side and route by state.
Running a clinic means keeping a real medical record, and that record has to sit in a HIPAA-compliant EHR — charting, e-prescribing, scheduling, telehealth visits, documents and an audit trail, under a signed BAA. It is not a database you should build yourself. We integrate an established EHR and sync it two ways with your platform, so the chart stays the source of clinical truth.
Surescripts-connected prescribing through pre-certified vendors. Never built from scratch, because certification is not something you want on your critical path.
Route each Rx to the right 503A or 503B facility by product, state, and stock. API where they have one, portal or fax bridge where they don't, because plenty still don't.
Recurring billing, dose changes, pauses, and refunds wired directly to prescription state. Not a storefront bolted onto a clinical system.
Order panels, ingest results into the chart, trend them over time. At-home phlebotomy when a patient won't make it to a draw site.
Refill check-ins, adherence nudges, progress dashboards, side-effect reporting. The things that keep a subscriber past month three.
We name examples, not a fixed stack. The orchestration, the compliance enforcement, and the fit to your model are what we tailor to you.
The complete patient flow for a compliant peptide platform — every step we build for you.
Compliant platforms enforce prescription gates at every step. No Rx = no access.
Scope this flowNo per-seat licensing, no revenue share, no platform fee that scales with your success. Once the build is paid for, every incremental patient is yours.
Your brand end to end: email, checkout, portal, packaging. Patients subscribe to you, not to a white-label interface with your logo on it.
Intake responses, adherence, outcomes, lab trends, churn signals. The asset that lets you optimize protocol and price, and the one thing you can never get back later.
A pharmacy raises prices or a vendor's margins slip, and you move. Modular by design, not locked to one stack.
When the rules move, it's a config change, not a rebuild. Your platform adapts the same week.
You own the code, the data, and the patient relationships. That's what makes a company worth buying, not a rented storefront.
Not a chatbot bolted onto a pharmacy. AI earns its place by removing work from your providers without ever removing them from the decision. Every use here is provider-supervised by design.
No contraindications, complete history, standard protocol. Surfaced with a pre-drafted summary so review takes seconds, not minutes.
Ambiguous answers, an interaction to weigh, or missing labs. Flagged with the specific concern quoted from the intake.
A hard contraindication or a red-flag symptom. Routed to a mandatory video visit before anything proceeds.
This platform is built by Light‑it, a digital health product studio, not a generic dev shop. We've shipped prescription and telehealth platforms for many clients across this market, which is why the compliant core already exists instead of being invented on your budget.
What happens next: a scoping call, not a pitch. We map your model against the current regulatory picture and tell you what building it right actually takes. Straight answers, including when the answer is "wait."
It's with our team and we'll reply within one business day. If it's urgent, reach us directly at hello@peptidesplatform.com.
Legally, peptides can only be sold through licensed compounding pharmacies with a valid prescription. Selling them as unregulated research chemicals for human use is illegal and being actively prosecuted. In July 2026 an FDA advisory committee recommended six of seven reviewed peptides for the 503A compounding list, but a recommendation is not an authorization: until the FDA completes formal notice-and-comment rulemaking, those peptides still cannot be lawfully compounded. Build your catalog around what your counsel and your pharmacy partners will sign off on today, not around what the committee voted for.
Whatever your prescribing providers are comfortable with and your pharmacy partners can compound under a valid prescription — today that is mostly GLP-1 variants. Names like BPC-157 and TB-500 came off Category 2 in April 2026 and were recommended by an advisory committee in July, but they are not lawfully compoundable yet and won't be until rulemaking closes. We build the catalog so adding or retiring a molecule is a config change rather than a rebuild, which is what lets you move in the week your counsel says you can.
At minimum: patient and provider portals, e-prescribing connected to Surescripts, compounding pharmacy integration with fulfillment tracking, prescription-gated payments, and labs or monitoring. The critical part is that these are integrated, so a patient can only pay for what a licensed provider prescribed.
This is the single most expensive mistake in the category. A generic storefront with no connection to a clinical system has no idea whether a prescription exists, what it's for, or whether it's still valid, so patients can buy things they were never prescribed and refills keep processing after an Rx lapses. Billing has to be tied to the prescription record at the database level, and access has to expire on its own. That's not a plugin. It's the architecture.
A compliant core can go live in a matter of weeks by starting from pre-integrated components. Timeline scales with the modules you add, such as pharmacy routing, provider networks, labs, and an AI intake layer.
No. You can start with managed provider and pharmacy vendors, then move to direct 503A integration as you scale. Direct integration removes the middleman and improves per-prescription margins, at the cost of more operational lift upfront.
Cost depends on scope. A compliant foundation plus the modules you select determines the range. A scoping call refines it against your workflows, states, and clinical model.
You do. It's a fixed build, and when it's paid for it's yours: code, data, and patient relationships.
A hybrid. Buy the proven, compliant basics so you launch fast, then build the custom layer that makes you defensible: your intake logic, adherence model, and data. Off-the-shelf alone tends to break the moment regulations shift.
White-label gets you live fast with a product you don't own, that looks like every other licensee, and whose roadmap you don't control. Sometimes that's the right call if you're validating an idea cheaply. We're the choice when the portal is the business: your own funnel and conversion model, your own partner contracts, your own data, and the ability to respond to a regulatory change the same week it happens instead of waiting on a vendor.
Compliance is enforced in the architecture, not bolted on afterward. Billing is tied to the prescription at the database level, every vendor handling protected health data signs a BAA, and the infrastructure is HIPAA-ready from day one.
No. We build to the regulatory model your counsel signs off on, and we'll flag when an architecture choice creates exposure.
You go live and we keep shipping. Post-launch we handle iteration, new integrations, and regulatory changes as they land. You own the platform, so support is a partnership on your terms, not a subscription you're locked into.